Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 Trial at 5 years median follow-up (MFU).

@article{Crown2006DocetaxelG,
  title={Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 Trial at 5 years median follow-up (MFU).},
  author={John P. A. Crown and Prudence Francis and Angelo di Leo and Marc Buyse and Ana Balil and Michael Q. Anderson and B O Nordenskj{\"o}ld and Raimund Jakesz and Jorge H Gutierrez and Martine J. Piccart},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={LBA519}
}
LBA519 Background: The activity of T in metastatic BrCa mandated evaluation as adjRx. We compared the efficacy of T with, or after A, both followed by CMF (cyclophosphamide/ methotrexate/ 5-fluorouracil), versus non-T adjRx. METHODS Random assignment trial in resected N+ pts, 18-70 yrs, stratified by: center, 1-3 vs >3 nodes and age <50 vs ≥50. The treatment arms were (mg/m2, intravenously unless otherwise stated): Ia: A 75 q 3 weeks × 4 ⋄ CMF ×3 (oral C 100 day 1-14, F 600 + M 40 d 1+8; q 28… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 3 Excerpts

Similar Papers

Loading similar papers…